Relapses and progression of disability in multiple sclerosis.

被引:953
作者
Confavreux, C
Vukusic, S
Moreau, T
Adeleine, P
机构
[1] Hop Neurol, EDMUS Coordinating Ctr, F-69394 Lyon 03, France
[2] Hop Neurol, Serv Neurol A, F-69394 Lyon 03, France
[3] Hospices Civils Lyon, Unite Biostat & Informat Med, Lyon, France
关键词
D O I
10.1056/NEJM200011163432001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The influence of the patterns of onset of multiple sclerosis and relapses of the disease on the time course of irreversible disability is controversial. Methods: In 1844 patients who had had multiple sclerosis for a mean (+/-SD) of 11+/-10 years, we determined the time of the clinical onset of the disease, the initial course (relapsing-remitting or progressive) and the subsequent course (relapsing-remitting, secondary progressive, or primary progressive), the times of relapses, the time to the onset of irreversible disability, and the time course of progressive, irreversible disability. We used three scores on the Kurtzke Disability Status Scale (range, 0 to 10, with higher scores indicating more severe disability) as measures of the severity and progression of disability: a score of 4 (limited walking ability but able to walk more than 500 m without aid or rest), a score of 6 (ability to walk with unilateral support no more than 100 m without rest), and a score of 7 (ability to walk no more than 10 m without rest while leaning against a wall or holding onto furniture for support). We used Kaplan-Meier analyses to determine the influence of relapses on the time to the onset of irreversible disability. Results: The median times from the onset of multiple sclerosis to the assignment of a score of 4, a score of 6, and a score of 7 on the disability scale were longer among the 1562 patients with a relapsing-remitting onset of disease (11.4, 23.1, and 33.1 years, respectively) than among the 282 patients who had progressive disease from the onset (0.0, 7.1, and 13.4 years, respectively; P<0.001 for all comparisons). In contrast, the times from the assignment of a score of 4 to a score of 6 were similar in the two groups (5.7 and 5.4 years, P=0.74). The time course of progressive, irreversible disease among patients with the primary progressive type of multiple sclerosis was not affected by the presence or absence of superimposed relapses. Conclusions: Among patients with multiple sclerosis, relapses do not significantly influence the progression of irreversible disability. (N Engl J Med 2000; 343:1430-8.) (C) 2000, Massachusetts Medical Society.
引用
收藏
页码:1430 / 1438
页数:9
相关论文
共 26 条
  • [1] Multiple sclerosis that is progressive from the time of onset -: Clinical characteristics and progression of disability
    Andersson, PB
    Waubant, E
    Gee, L
    Goodkin, DE
    [J]. ARCHIVES OF NEUROLOGY, 1999, 56 (09) : 1138 - 1142
  • [2] MULTIPLE SCLEROSIS-LIKE ILLNESS OCCURRING WITH HUMAN IMMUNODEFICIENCY VIRUS-INFECTION
    BERGER, JR
    SHEREMATA, WA
    RESNICK, L
    ATHERTON, S
    FLETCHER, MA
    NORENBERG, M
    [J]. NEUROLOGY, 1989, 39 (03) : 324 - 329
  • [3] Coles AJ, 1999, ANN NEUROL, V46, P296, DOI 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO
  • [4] 2-#
  • [5] EDMUS, A EUROPEAN DATABASE FOR MULTIPLE-SCLEROSIS
    CONFAVREUX, C
    COMPSTON, DAS
    HOMMES, OR
    MCDONALD, WI
    THOMPSON, AJ
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1992, 55 (08) : 671 - 676
  • [6] COURSE AND PROGNOSIS OF MULTIPLE-SCLEROSIS ASSESSED BY THE COMPUTERIZED DATA-PROCESSING OF 349 PATIENTS
    CONFAVREUX, C
    AIMARD, G
    DEVIC, M
    [J]. BRAIN, 1980, 103 (JUN) : 281 - 300
  • [7] The natural history of multiple sclerosis: a geographically based study - 5. The clinical features and natural history of primary progressive multiple sclerosis
    Cottrell, DA
    Kremenchutzky, M
    Rice, GPA
    Koopman, WJ
    Hader, W
    Baskerville, J
    Ebers, GC
    [J]. BRAIN, 1999, 122 : 625 - 639
  • [8] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    DUQUETTE, P
    GIRARD, M
    DESPAULT, L
    DUBOIS, R
    KNOBLER, RL
    LUBLIN, FD
    KELLEY, L
    FRANCIS, GS
    LAPIERRE, Y
    ANTEL, J
    FREEDMAN, M
    HUM, S
    GREENSTEIN, JI
    MISHRA, B
    MULDOON, J
    WHITAKER, JN
    EVANS, BK
    LAYTON, B
    SIBLEY, WA
    LAGUNA, J
    KRIKAWA, J
    PATY, DW
    OGER, JJ
    KASTRUKOFF, LF
    MOORE, GRW
    HASHIMOTO, SA
    MORRISON, W
    NELSON, J
    GOODIN, DS
    MASSA, SM
    GUTTERIDGE, E
    ARNASON, BGW
    NORONHA, A
    REDER, AT
    MARTIA, R
    EBERS, GC
    RICE, GPA
    LESAUX, J
    JOHNSON, KP
    PANITCH, HS
    BEVER, CT
    CONWAY, K
    WALLENBERG, JC
    BEDELL, L
    VANDENNOORT, S
    WEINSHENKER, B
    WEISS, W
    REINGOLD, S
    PACHNER, A
    TAYLOR, W
    [J]. NEUROLOGY, 1993, 43 (04) : 655 - 661
  • [9] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
    Ebers, GC
    Rice, G
    Lesaux, J
    Paty, D
    Oger, J
    Li, DKB
    Beall, S
    Devonshire, V
    Hashimoto, S
    Hooge, J
    Kastrukoff, L
    Krieger, C
    Mezei, M
    Seland, P
    Vorobeychi, G
    Morrison, W
    Nelson, J
    Freedman, MS
    Chrisie, S
    Nelson, R
    Rabinovitch, H
    Freedman, C
    Hartung, HP
    Rieckmann, P
    Archelos, J
    Jung, S
    Weilbach, F
    Flachenecke, P
    Sauer, J
    Hommes, O
    Jongen, P
    Brouwer, S
    McLeod, J
    Pollard, J
    Ng, R
    Sandberg-Wollheim, M
    Källén, K
    Nilsson, P
    Ekberg, R
    Lundgren, A
    Jadbäck, G
    Wikström, J
    Multanen, J
    Valjakka, M
    Carton, H
    Lissoir, F
    Declerq, I
    Vieren, M
    Peeters, E
    Dubois, B
    [J]. LANCET, 1998, 352 (9139) : 1498 - 1504
  • [10] Ebers GC, 1999, LANCET, V353, P678